SATI.AQSE

Sativa Investments plc
Sativa Group PLC - Another Record Month of Revenues
11th August 2020, 10:02
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7985V
Sativa Group PLC
11 August 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. FOR IMMEDIATE RELEASE

Sativa Group Plc
("Sativa" or the "Company" or the "Group")

Another Record Month

11 August 2020

Sativa Group Plc [AQSE: SATI], the UK's leading quoted CBD wellness and medicinal cannabis company, has recorded a record month of revenues for the Group in July.

We are pleased to announce that our strong group sales momentum continues with another record-breaking month of sales for the month of July. There continues to be very strong demand for our Goodbody sanitiser range which is sold to both consumers and custom branded for corporate clients.

We continue to develop our core CBD offer, with the launch of our newly combined Goodbody website "goodbodystore.com" which features both our Wellness and Botanicals ranges has gone extremely well. This site provides the platform for product line expansion and focused efforts to drive sales growth. The new Goodbody Wellness line featuring CBD with vitamin D is being received very well by both consumers and retailers.

Henry Lees-Buckley, Chief Executive Officer of Sativa, said: "We are delighted to see the continued sales momentum. We are working aggressively to build out both the platform online and expand the product range to anticipate and satisfy consumer demand. Our focus on regulatory compliance holds steadfast and we are actively engaged in the FSA Novel Foods accreditation process. Our combination with StillCanna Inc is on track and is expected close in early to mid-September. This creates a true "Seed to consumer CBD company".

The Directors of the Company accept responsibility for the contents of this announcement.

Henry Lees-Buckley
Chief Executive Officer
Sativa Group Plc
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk
www.sativagroup.co.uk

Joseph Colliver
Chief Financial Officer
Sativa Group Plc
+44 (0) 20 7971 1255
enquiries@sativagroup.co.uk
www.sativagroup.co.uk

AQSE Growth Market Corporate Adviser

Corporate Finance 
Guy Miller/Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7220 9795

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NEXEANPFFSPEEEA ]]>
TwitterFacebookLinkedIn